Pfizer (PFE) agreed to pay about $59.7 million to settle allegations that Biohaven Pharmaceutical Holding, before being acquired by Pfizer, defrauded several US health care programs by paying kickbacks to doctors to drive prescriptions of its Nurtec ODT drug for migraine, the US Department of Justice said Friday.
According to the statement, Biohaven allegedly paid "improper remuneration" to healthcare professionals from March 1, 2020, through September 30, 2022, to induce them to prescribe Nurtec ODT and subsequently submit false claims to Medicare and other federal healthcare programs.
The Justice Department said the settlement also resolves a suit filed by a former Biohaven sales representative. However, it was noted that the settlement only resolved allegations, and no liability was determined.
Pfizer and Biohaven Pharmaceutical Holding did not immediately respond to MT Newswires' requests for comments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。